Lars Fruergaard Jørgensen, Novo Nordisk CEO (Chris Ratcliffe/Bloomberg via Getty Images)

July 11, 2022 07:32 AM EDTUpdated 09:57 AM

Two years after scrapping three hemophilia trials, Novo Nordisk plots route to FDA with new PhIII data

Max Gelman

Senior Editor

Novo Nordisk continues to move forward with its once-daily monoclonal antibody for hemophilia A or B treatment aiming to stop excessive bleeding events before they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two years after scrapping three hemophilia trials, Novo Nordisk plots route to FDA with new PhIII data

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Two years af­ter scrap­ping three he­mo­phil­ia tri­als, No­vo Nordisk plots route to FDA with new PhI­II da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Two years after scrapping three hemophilia trials, Novo Nordisk plots route to FDA with new PhIII data

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration